Your browser doesn't support javascript.
Mostrar: 20 | 50 | 100
Resultados 1 - 20 de 133
Filtrar
2.
Medicine (Baltimore) ; 98(11): e14910, 2019 Mar.
Artigo em Inglês | MEDLINE | ID: mdl-30882710

RESUMO

The relevance of LP(a), Hcy, and D-D in ischemic cerebrovascular disease remains undefined. This study aimed to assess the associations of plasma LP(a), Hcy and D-D levels with the subtype of ischemic cerebrovascular disease.Patients with ischemic cerebrovascular disease admitted to the Taixing People's Hospital were retrospectively enrolled from November 2017 to July 2018. Immunoturbidimetry was used to assess 119 LAA, 107 SAO, and 112 TIA patients for plasma LP(a), Hcy, and D-D levels.Plasma LP(a), Hcy, and D-D levels in the large artery atherosclerosis (LAA) group were significantly lower than those of the transient ischemic attack (TIA) group (all P < .05). LP(a), Hcy, and D-D levels were significantly reduced in the SAO group compared with the TIA group (both P < .05). The LAA and SAO groups showed comparable values for all the above parameters (P > .05).LP(a), Hcy, and D-D levels differ according to the subtype of ischemic cerebrovascular disease.


Assuntos
Transtornos Cerebrovasculares/sangue , Isquemia/sangue , Acidente Vascular Cerebral/sangue , Idoso , Análise de Variância , Hidrolases de Éster Carboxílico/análise , Hidrolases de Éster Carboxílico/sangue , Transtornos Cerebrovasculares/classificação , Feminino , Humanos , Hidrocarbonetos Clorados/análise , Hidrocarbonetos Clorados/sangue , Lipoproteína(a)/análise , Lipoproteína(a)/sangue , Masculino , Pessoa de Meia-Idade , Estudos Retrospectivos , Estatísticas não Paramétricas
3.
Endocrinol. diabetes nutr. (Ed. impr.) ; 65(2): 74-83, feb. 2018. graf, tab
Artigo em Espanhol | IBECS | ID: ibc-171948

RESUMO

Objetivo: Determinar el comportamiento de la relación triglicéridos/colesterol HDL (TG/cHDL) como indicador de riesgo cardiometabólico en niños y adolescentes escolarizados de la ciudad de Mérida. Métodos: Se estudió a 1.292 niños y adolescentes entre 7 y 18 años de edad, de instituciones educativas del Municipio Libertador. Se registraron medidas antropométricas y la presión arterial. Se determinaron glucemia, insulina y lípidos en ayunas. Se calcularon la relación TG/cHDL y los índices HOMA-IR y QUICKI. Se realizó la clasificación de individuos con riesgo y sin riesgo cardiometabólico a partir de la presencia o no de 2 o más factores de riesgo. Se determinaron puntos de corte de la relación TG/cHDL a través de la construcción de curvas operador receptor (COR). Resultados: La relación TG/cHDL presentó medias significativamente superiores en individuos púberes (2,2 ± 1,7) en comparación con prepúberes (1,8 ± 1,5; p = 0,001), sin diferencias según el género. El 14,7% (n = 192) de los participantes presentaba 2 o más factores de riesgo y los valores de la relación TG/cHDL fueron significativamente mayores en comparación con aquellos sin riesgo (3,5 ± 2,9 frente a 1,6 ± 0,8 en prepúberes y 4,1 ± 3,5 frente a 1,8 ± 0,9 en púberes; p = 0,0001). De acuerdo con el riesgo cardiometabólico, se obtuvieron puntos de corte para la relación TG/cHDL de 1,8 y 2,5 en prepúberes y púberes, respectivamente. Estos puntos de corte muestran riesgos (odds ratios) superiores a 2,5 para alteraciones como síndrome metabólico, colesterol no HDL elevado, obesidad abdominal y HOMA-IR elevado. Conclusión: En esta muestra de niños y adolescentes, la relación TG/cHDL elevada demostró ser un buen marcador para predecir riesgo cardiometabólico (AU)


Objective: To determine the behavior of the triglycerides/HDL-cholesterol ratio (TG/HDL) as a cardiometabolic risk marker in children and adolescents from Mérida, Venezuela. Methods: A total of 1292 children and adolescents aged 7-18 years who attended educational institutions in the Libertador Municipality were enrolled into this study. Anthropometric measurements and blood pressure values were recorded. Fasting blood glucose, insulin and lipid levels were measured. The TG/HDL ratio, HOMA-IR, and QUICKI indexes were calculated. Subjects were categorized as with and without cardiometabolic risk based on the presence or absence of 2or more risk factors. Cut-off points for the TG/HDL ratio were determined by constructing ROC curves. Results: Significantly higher mean TG/HDL ratios were found in pubertal (2.2 ± 1.7) as compared to prepubertal subjects (1.8 ± 1.5; P=.001), with no sex differences. Two or more risk factors were found in 14.7% (n=192) of the participants, in whom TG/HDL ratios were significantly higher as compared to those with no risk (3.5±2.9 versus 1.6±0.8 in prepubertal and 4.1 ± 3.5 versus 1.8 ± 0.9 in pubertal subjects; P=.0001). According to cardiometabolic risk, cut-off points for the TG/HDL ratio of 1.8 and 2.5 were found for prepubertal and pubertal children respectively. These cut-off points showed risks (odds ratio) higher than 2.5 for conditions such as metabolic syndrome, elevated non-HDL-C, abdominal obesity, and elevated HOMA-IR. Conclusion: In this sample of children and adolescents, an elevated TG/HDLc ratio was found to be a good marker for predicting cardiometabolic risk (AU)


Assuntos
Humanos , Masculino , Feminino , Criança , Doenças Cardiovasculares/prevenção & controle , Triglicerídeos/análise , Colesterol/análise , Lipoproteína(a)/análise , Lipídeos/análise , Estado Nutricional , Venezuela/epidemiologia , Antropometria/métodos , Pressão Arterial , Índice Glicêmico , Insulina/análise , Estudos Transversais/métodos , Testes de Química Clínica/métodos
4.
Aging Clin Exp Res ; 29(Suppl 1): 185-190, 2017 Feb.
Artigo em Inglês | MEDLINE | ID: mdl-27822883

RESUMO

BACKGROUND: The mechanism for hypercoagulability in malignancy is not entirely understood. Although several studies report contrasting finding about the link between elevated plasma levels of the lipoprotein(a) [Lp(a)] and the possible recurrence of venous thromboembolism, we perform a study to evaluate the impact of the Lp(a) in the development of portal vein thromboembolism (PVT) in patients with HCC. METHODS: We compared 44 PVT patients with 50 healthy subjects and 50 HCC patients. RESULTS: The comparison between PVT patients and HCC showed in the former the mean value of serum lipoprotein levels was higher than 37.3 mg/dl (p = 0.000). The comparison between PVT versus healthy controls showed that in the former, mean value of serum lipoprotein levels was higher than 75 mg/dl (p = 0.000). The predictive value test of serum lipoprotein(a) on PVT was 0.72 and on HCC was 0.83. The odds ratio of lipoprotein(a) was 9.21 on PVT and 6.33 on HCC. CONCLUSION: Patients with PVT and HCC showed a statistical significant serum lipoprotein(a) level higher than the subjects with HCC and no PVT or the healthy subject. So we assume a role of lipoprotein(a) as predictor of venous thromboembolism in neoplastic patients.


Assuntos
Carcinoma Hepatocelular , Lipoproteína(a)/sangue , Neoplasias Hepáticas , Veia Porta/diagnóstico por imagem , Trombose Venosa , Idoso , Carcinoma Hepatocelular/sangue , Carcinoma Hepatocelular/complicações , Carcinoma Hepatocelular/patologia , Feminino , Humanos , Lipoproteína(a)/análise , Neoplasias Hepáticas/sangue , Neoplasias Hepáticas/complicações , Neoplasias Hepáticas/patologia , Masculino , Pessoa de Meia-Idade , Valor Preditivo dos Testes , Estatística como Assunto , Ultrassonografia Doppler/métodos , Trombose Venosa/sangue , Trombose Venosa/diagnóstico , Trombose Venosa/etiologia
6.
Biomark Med ; 10(4): 397-402, 2016.
Artigo em Inglês | MEDLINE | ID: mdl-26999640

RESUMO

AIM: The association between Lipoprotein (a) (Lp [a]) and common carotid intima media thickness (IMT) has been evaluated in 222 menopausal women. MATERIAL & METHODS: Lp (a) and IMT were measured, carotid ultrasound examination (B-Mode imaging) was performed and mean max IMT was calculated. RESULTS: Lp (a) was significantly lower in women with metabolic syndrome (MS). In a multivariate analysis Lp (a) showed the following odds ratio (OR; all p < 0.05) of having common carotid IMT (≥1.30 mm): 1.03, adjusted for age, low-density lipoprotein cholesterol (LDL) and waist circumference; 1.02, adjusted for age LDL, homeostatic assessment model (HOMA). In women without MS, after controlling for age, LDL and waist circumference, we found the following OR for increased IMT (≥1.30; OR: 1.03; for Lp [a]); 1.02 adjusted for age, LDL and HOMA (all p < 0.05). In women with MS these relationships were not statistically significant. CONCLUSION: Lp (a) gives additional information in the risk assessment for atherosclerotic cardiovascular disease, especially in menopausal women without MS.


Assuntos
Aterosclerose/diagnóstico , Lipoproteína(a)/análise , Adulto , Idoso , Aterosclerose/complicações , Glicemia/análise , Pressão Sanguínea , Espessura Intima-Media Carotídea , LDL-Colesterol/sangue , Feminino , Humanos , Menopausa , Síndrome Metabólica/complicações , Pessoa de Meia-Idade , Análise Multivariada , Razão de Chances , Fatores de Risco , Circunferência da Cintura
7.
J. physiol. biochem ; 70(4): 1021-1028, dic. 2014. ilus
Artigo em Inglês | IBECS | ID: ibc-131435

RESUMO

Atherosclerosis remains the leading cause of severe cardiovascular complications such as cardio- and cerebrovascular events. Given that prevention and early intervention play important roles in the reduction of cardiovascular complications associated with atherosclerosis, it is critical to better understand how to target the modifiable risk factors, such as diet, in order to best minimize their contributions to the development of the disease. Studies have shown that various dietary sources of protein can affect blood lipid levels, a modifiable risk factor for atherosclerosis, either positively or negatively. This clearly highlights that not all proteins are «created equal». For example, consumption of diets high in either animal- or vegetable-based sources of protein have resulted in varied and inconsistent effects on blood cholesterol levels, often depending on the amino acid composition of the protein and the species investigated. Careful consideration of the source of dietary protein may play an important role in the prevention of atherosclerosis and subsequent cardiovascular complications. Given the recent focus on high protein diets, an emphasis on controlled studies in the area is warranted. The goal of this review is to present the current state of the literature that examines the effects of casein, a commonly utilized animal-based protein, on blood cholesterol levels and the varying effects noted in both animals and humans (AU)


Assuntos
Humanos , Animais , Caseínas/farmacocinética , Hipercolesterolemia/fisiopatologia , Proteínas de Soja/farmacocinética , Aterosclerose/fisiopatologia , Lipoproteína(a)/análise , Colesterol/sangue
8.
Arq Bras Cardiol ; 103(1): 76-84, 2014 Jul.
Artigo em Inglês, Português | MEDLINE | ID: mdl-25120086

RESUMO

The chemical structure of lipoprotein (a) is similar to that of LDL, from which it differs due to the presence of apolipoprotein (a) bound to apo B100 via one disulfide bridge. Lipoprotein (a) is synthesized in the liver and its plasma concentration, which can be determined by use of monoclonal antibody-based methods, ranges from < 1 mg to > 1,000 mg/dL. Lipoprotein (a) levels over 20-30 mg/dL are associated with a two-fold risk of developing coronary artery disease. Usually, black subjects have higher lipoprotein (a) levels that, differently from Caucasians and Orientals, are not related to coronary artery disease. However, the risk of black subjects must be considered. Sex and age have little influence on lipoprotein (a) levels. Lipoprotein (a) homology with plasminogen might lead to interference with the fibrinolytic cascade, accounting for an atherogenic mechanism of that lipoprotein. Nevertheless, direct deposition of lipoprotein (a) on arterial wall is also a possible mechanism, lipoprotein (a) being more prone to oxidation than LDL. Most prospective studies have confirmed lipoprotein (a) as a predisposing factor to atherosclerosis. Statin treatment does not lower lipoprotein (a) levels, differently from niacin and ezetimibe, which tend to reduce lipoprotein (a), although confirmation of ezetimibe effects is pending. The reduction in lipoprotein (a) concentrations has not been demonstrated to reduce the risk for coronary artery disease. Whenever higher lipoprotein (a) concentrations are found, and in the absence of more effective and well-tolerated drugs, a more strict and vigorous control of the other coronary artery disease risk factors should be sought.


Assuntos
Lipoproteína(a)/fisiologia , Apolipoproteínas A/química , Apolipoproteínas A/genética , Humanos , Lipoproteína(a)/análise , Lipoproteína(a)/metabolismo , Fatores de Risco
9.
Arq. bras. cardiol ; 103(1): 76-84, 07/2014. tab
Artigo em Inglês | LILACS | ID: lil-718102

RESUMO

The chemical structure of lipoprotein (a) is similar to that of LDL, from which it differs due to the presence of apolipoprotein (a) bound to apo B100 via one disulfide bridge. Lipoprotein (a) is synthesized in the liver and its plasma concentration, which can be determined by use of monoclonal antibody-based methods, ranges from < 1 mg to > 1,000 mg/dL. Lipoprotein (a) levels over 20-30 mg/dL are associated with a two-fold risk of developing coronary artery disease. Usually, black subjects have higher lipoprotein (a) levels that, differently from Caucasians and Orientals, are not related to coronary artery disease. However, the risk of black subjects must be considered. Sex and age have little influence on lipoprotein (a) levels. Lipoprotein (a) homology with plasminogen might lead to interference with the fibrinolytic cascade, accounting for an atherogenic mechanism of that lipoprotein. Nevertheless, direct deposition of lipoprotein (a) on arterial wall is also a possible mechanism, lipoprotein (a) being more prone to oxidation than LDL. Most prospective studies have confirmed lipoprotein (a) as a predisposing factor to atherosclerosis. Statin treatment does not lower lipoprotein (a) levels, differently from niacin and ezetimibe, which tend to reduce lipoprotein (a), although confirmation of ezetimibe effects is pending. The reduction in lipoprotein (a) concentrations has not been demonstrated to reduce the risk for coronary artery disease. Whenever higher lipoprotein (a) concentrations are found, and in the absence of more effective and well-tolerated drugs, a more strict and vigorous control of the other coronary artery disease risk factors should be sought.


A partícula de lipoproteína (a) apresenta estrutura semelhante à da LDL, diferenciando-se pela presença da apolipoproteína (a) ligada por uma ponte dissulfeto à apolipoproteína B. Sua síntese ocorre no fígado e sua concentração plasmática varia de < 1 mg a > 1.000 mg/dL, podendo ser dosada de rotina em laboratório clínico por método baseado em anticorpos monoclonais. Acima de 20 a 30 mg/dL o risco de desenvolvimento de doença cardiovascular aumenta em cerca de duas vezes, o que não é válido para os afrodescendentes, que já apresentam normalmente níveis mais altos dessa lipoproteína, do que caucasianos e orientais. Entretanto, o risco para indivíduos negros também deve ser levado em conta. Gênero e idade exercem pouca influência na concentração de lipoproteína (a). A homologia com o plasminogênio, que interfere na cascata fibrinolítica, pode ser um mecanismo da aterogenicidade da lipoproteína (a). Entretanto, a deposição direta na parede da artéria também é um dos mecanismos possíveis, sendo a lipoprotrína (a) mais oxidável do que a LDL. De forma geral estudos prospectivos confirmam a lipoproteína (a) como fator predisponente à aterosclerose. O uso de estatinas não interfere no nível da lipoproteína (a), diferentemente da niacina e da ezetimiba, que promovem sua diminuição, embora essa última dependa de confirmação. Não está demonstrado que a redução de lipoproteína (a) resulte em diminuição de risco de doença arterial coronária. Diante de concentrações mais elevadas de lipoproteína (a) e na falta de medicações mais efetivas e de boa tolerabilidade, deve-se, pelo menos, procurar controlar, de forma mais rigorosa, os outros fatores de risco de doença arterial coronária.


Assuntos
Humanos , Lipoproteína(a)/fisiologia , Apolipoproteínas A/química , Apolipoproteínas A/genética , Lipoproteína(a)/análise , Lipoproteína(a)/metabolismo , Fatores de Risco
10.
Neuro Endocrinol Lett ; 34(4): 309-13, 2013.
Artigo em Inglês | MEDLINE | ID: mdl-23803869

RESUMO

OBJECTIVE: Identification of lipoprotein subfractions in lipoprotein profile by Lipoprint LDL system, where a lipoprotein(a), an independent risk factor for the development of cardiovascular disease, migrates with. The concentration of lipoprotein(a) in serum over 0.3 g/l increases the risk of athero-thrombosis and a brain stroke. The persons with increased levels of lipoprotein(a) and contemporarily increased cholesterol level in serum, are at increased risk of the inception of cardiovascular or cerebrovascular event even 3-times. PATIENTS AND METHODS: In a general group of subjects with increased serum concentration of lipoprotein(a) a lipoprotein profile analysis was performed. The general group of subjects was divided into two groups: subgroup with the lipoprotein(a) concentration in the range between 0.3-0.8 g/l and a subgroup with the lipoprotein(a) concentration over 0.8 g/l, to learn if the lipoprotein(a) particles of different serum concentration and different size do not migrate in different positions of the lipoprotein spectrum. For the analysis of serum lipoproteins an innovated electrophoresis method on polyacrylamide gel (PAG) - Lipoprint LDL system USA, was used. Lipids: a total cholesterol and triglycerides in serum were analysed by an enzymatic method CHOD PAP (Roche Diagnostics, FRG), lipoprotein(a) was analysed by an immuno-nephelometric method (Roche Diagnostics, FRG). RESULTS: In the Lipoprint LDL system using a polyacrylamide gel (PAG) for the lipoprotein separation, lipoprotein(a) migrates in the position IDL2-IDL3. In the band of IDL2 a high Lp(a) values can be identified, when the increment of IDL2 subfraction is over the value of 0.015 g/l, i.e. 15 mg/dl (reference range for IDL2) and when the increment of IDL3 subfraction is over the value of 25 mg/dl, i.e. 0.025 g/l (reference range for IDL3). CONCLUSIONS: A clear contribution of new method is: identification of the lipoprotein subpopulations where the lipoprotein(a) migrates with different migration position for the mild increased lipoprotein(a) concentration and high lipoprotein(a) concentration in serum was not confirmed.


Assuntos
Eletroforese em Gel de Poliacrilamida/métodos , Hiperlipoproteinemias/diagnóstico , Lipoproteína(a)/análise , Eletroforese em Gel de Poliacrilamida/instrumentação , Feminino , Humanos , Lipoproteína(a)/sangue , Lipoproteínas/análise , Lipoproteínas/sangue , Masculino , Pessoa de Meia-Idade , Nefelometria e Turbidimetria
11.
Brain Res Bull ; 97: 48-52, 2013 Aug.
Artigo em Inglês | MEDLINE | ID: mdl-23727547

RESUMO

Lipoprotein-A (LpA) is an emerging independent risk factor for cerebro- and cardio-vascular diseases (CCVD). Recognizing its function and its normal distribution is of fundamental importance for a better understanding of CCVD patho-physiology. The present study evaluated plasma LpA levels of healthy university students using turbidimetric methods. Medians and inter-quartile differences obtained for male and female participants were 11.3mg/dL (3.1-30.7) and 20.9mg/dL (6.5-42.3), respectively, demonstrating a significant difference (P=0.017) between men and women. A third of students showed plasma concentrations above reference values. Our results indicate that 33% of students possess a hidden independent risk factor for CCVD. Multi-disciplinary evaluation and characterization of young individuals should be recommended in an attempt to take early preventive measures and to eliminate possible modifiable risk factors such as sedentary lifestyle, smoking, hypertension, obesity and atherogenic diet.


Assuntos
Doenças Cardiovasculares/diagnóstico , Transtornos Cerebrovasculares/diagnóstico , Lipoproteína(a)/análise , Adolescente , Adulto , Brasil , Estudos Transversais , Feminino , Humanos , Masculino , Fatores de Risco , Adulto Jovem
12.
Zhonghua Nan Ke Xue ; 19(3): 247-50, 2013 Mar.
Artigo em Chinês | MEDLINE | ID: mdl-23700732

RESUMO

OBJECTIVE: To explore the effect of seminal plasma lipoprotein (a) in abnormal semen liquefaction and its clinical significance. METHODS: According to The WHO Laboratory Manual for the Examination and Processing of Human Semen, we conducted semen routine analyses of 101 patients with abnormal semen liquefaction and 26 normal healthy controls. We added chymotrypsin to the semen for 30 minutes of incubation at 37 degrees C. When there were filaments, we centrifuged the semen and obtained the upper seminal plasma to determine the level of lipoprotein (a). RESULTS: The level of lipoprotein (a) was significantly higher in the 101 patients ([526.2 +/- 243.5] mg/L) than in the 26 normal controls ([296.9 +/- 105.2] mg/L) (P < 0.01) . CONCLUSION: Lipoprotein (a) can inhibit fibrin dissolution, and delayed fibrin dissolution in semen liquefaction may be related to the increased level of seminal plasma lipoprotein (a). The seminal plasma lipoprotein (a) level should be taken into account in the clinical diagnosis of male infertility caused by abnormal semen liquefaction.


Assuntos
Infertilidade Masculina/fisiopatologia , Lipoproteína(a)/análise , Sêmen/metabolismo , Adulto , Estudos de Casos e Controles , Humanos , Infertilidade Masculina/metabolismo , Masculino , Proteínas de Plasma Seminal/análise , Adulto Jovem
13.
Clin Chim Acta ; 413(13-14): 1071-6, 2012 Jul 11.
Artigo em Inglês | MEDLINE | ID: mdl-22406178

RESUMO

BACKGROUND: We developed an ultracentrifugation and high-performance liquid chromatography (HPLC) method for simultaneous measurement of cholesterol in serum high density lipoprotein (HDL) and low density lipoprotein (LDL) subfractions and lipoprotein (a) [Lp(a)]. METHODS: Serum aliquots of 0.05 ml were centrifuged at background densities of 1.006, 1.044 kg/l, and in the presence of ß-mercaptoethanol (ME) at background densities of 1.044, 1.063 and 1.125 kg/l for the separation of lipoprotein subfractions and Lp(a). Cholesterol levels in the ultracentrifugal bottom fractions were analyzed by HPLC. RESULTS: ME effectively dissociated Lp(a) into apolipoprotein (a) and Lp(a) remnant [Lp(a-)]. Lp(a-) showed a distinctive density distribution from that of the native Lp(a). Based on these data, a method was developed to separate lipoprotein into subfractions and Lp(a) by ultracentrifugation. The separated HDL and LDL subfractions were not contaminated with Lp(a). This method is highly precise with the total CVs for the measurement of HDL2-C, HDL3-C, LDLa-C, LDLb-C and Lp(a)-C 0.85%-2.66%, 0.87%-3.21%, 0.86%-1.11%, 2.59%-6.35% and 4.42%-12.29%, respectively. CONCLUSION: A new method for the separation of HDL and LDL subfractions and Lp(a) and simultaneous measurement of cholesterol by ultracentrifugation and HPLC have been established. It is precise and sensitive and can be used in research or clinical laboratories for lipoprotein profiling.


Assuntos
HDL-Colesterol/sangue , LDL-Colesterol/sangue , Cromatografia Líquida de Alta Pressão/métodos , Lipoproteína(a)/análise , Ultracentrifugação/métodos , Adulto , Feminino , Humanos , Masculino , Pessoa de Meia-Idade , Reprodutibilidade dos Testes
14.
Rinsho Byori ; 58(6): 606-12, 2010 Jun.
Artigo em Japonês | MEDLINE | ID: mdl-20662273

RESUMO

High-density lipoprotein (HDL) is the smallest lipoprotein, with a density range of 1.063-1.210. HDL plays a crucial role in reverse cholesterol transport. Epidemiological studies have consistently shown that HDL-cholesterol (HDL-C) is inversely correlated with the incidence of coronary heart disease (CHD). HDL is composed of heterogeneous particles with different compositions and functions. For more precise prediction of CHD, researchers measure HDL subfractions which are separated by various methods based on their physicochemical properties. In this article, we briefly review the methods for measuring HDL subfractions and their clinical significance. We also address future perspectives in HDL subfraction measurements in the "Era of HDL therapy."


Assuntos
Fracionamento Químico/métodos , HDL-Colesterol/análise , Lipoproteínas de Alta Densidade Pré-beta/análise , Lipoproteína(a)/análise , Aterosclerose/prevenção & controle , Biomarcadores/análise , Proteínas de Transferência de Ésteres de Colesterol/antagonistas & inibidores , HDL-Colesterol/isolamento & purificação , Doença das Coronárias/prevenção & controle , Lipoproteínas de Alta Densidade Pré-beta/isolamento & purificação , Humanos , Lipoproteína(a)/isolamento & purificação , Oxazolidinonas/uso terapêutico , Valor Preditivo dos Testes
15.
Rinsho Shinkeigaku ; 50(6): 404-8, 2010 Jun.
Artigo em Japonês | MEDLINE | ID: mdl-20593666

RESUMO

A 28-year-old man was admitted to our hospital because of severe headache and diplopia. Enhanced CT of the head revealed defects of contrast enhancement in the superior sagittal sinus and the right transverse sinus. Accordingly, he was diagnosed as suffering from cerebral venous thrombosis. The patient made a good recovery after receiving anticoagulant therapy. Investigations revealed a high plasma lipoprotein (a) [Lp (a)] level of 142 mg/ dl. We thought that his high Lp (a) level was associated with a thrombotic tendency. His mother also had an elevated plasma Lp (a) level of 45 mg/dl. Cerebral venous thrombosis of unknown etiology is not rare. In such patients, we should investigate the plasma Lp (a) level.


Assuntos
Veias Cerebrais , Lipoproteína(a)/análise , Trombose Venosa/diagnóstico , Adulto , Anticoagulantes/uso terapêutico , Biomarcadores/sangue , Humanos , Masculino , Fatores de Risco , Tomografia Computadorizada por Raios X , Trombose Venosa/tratamento farmacológico , Trombose Venosa/etiologia
16.
Clin Biochem ; 43(6): 571-5, 2010 Apr.
Artigo em Inglês | MEDLINE | ID: mdl-20060390

RESUMO

OBJECTIVE: To evaluate clinical value of oxidized lipoprotein(a) [ox-Lp(a)] levels. DESIGN AND METHODS: Ox-Lp(a) were measured by 2 ELISAs using antibodies against ox-Lp(a) [ox-Lp(a)1] or oxidized low-density lipoprotein [ox-Lp(a)2], and studied in 161 acute coronary syndromes (ACS) patients, 114 stable coronary artery disease (CAD) and 100 control subjects. RESULTS: Ox-Lp(a)1 was found related with ox-Lp(a)2 (r=0.864, P=0.000). Controlling for plasma lipids, Lp(a) and clinical characteristics, odds ratios of ox-Lp(a)1 on ACS and stable CAD were 5.06 (95% confidence interval 1.82-14.04) and 2.20 (0.78-6.22); those of ox-Lp(a)2 were 3.37 (1.07-10.63) and 1.35 (0.41-4.48), respectively. Receiver-operating characteristic curve analysis confirmed that performances of ox-Lp(a)1 were significantly superior to those for ox-Lp(a)2 in ACS (area: 0.803 vs. 0.723, P<0.001) and stable CAD (area: 0.670 vs. 0.607, P<0.01). CONCLUSION: Ox-Lp(a) levels using antibodies against ox-Lp(a) may represent a better risk marker than those using antibodies against oxidized low-density lipoprotein for ACS and stable CAD.


Assuntos
Síndrome Coronariana Aguda/sangue , Anticorpos/farmacologia , Doença da Artéria Coronariana/sangue , Lipoproteína(a)/análise , Lipoproteína(a)/imunologia , Lipoproteínas LDL/imunologia , Síndrome Coronariana Aguda/diagnóstico , Síndrome Coronariana Aguda/metabolismo , Idoso , Estudos de Casos e Controles , Doença da Artéria Coronariana/diagnóstico , Doença da Artéria Coronariana/metabolismo , Progressão da Doença , Ensaio de Imunoadsorção Enzimática/métodos , Feminino , Humanos , Lipoproteína(a)/sangue , Lipoproteína(a)/metabolismo , Lipoproteínas LDL/análise , Lipoproteínas LDL/sangue , Masculino , Pessoa de Meia-Idade , Oxirredução , Valor Preditivo dos Testes , Curva ROC , Índice de Gravidade de Doença
17.
Clin Appl Thromb Hemost ; 16(2): 214-7, 2010 Apr.
Artigo em Inglês | MEDLINE | ID: mdl-19752039

RESUMO

Lipoprotein (a) is a cholesterol-rich plasma lipoprotein with a lipid composition similar to that of low-density lipoproteins (LDL). Many prospective and case-control studies identified elevated levels of lipoprotein (a) as a risk factor for premature myocardial infarction and stroke. Elevated lipoprotein (a) has been identified as a genetically determined risk factor for stroke in young adults, but only preliminary data are available on its role as a risk factor for ischemic stroke in infants and children.Fifty two children with arterial ischemic stroke and 78 age- and sex-matched healthy children were studied. Data of this study indicate that 26.9% of children with arterial ischemic stroke had high lipoprotein (a) levels in comparison with the age matched healthy control group.Measurement of lipoprotein (a) should be included in screening programs performed in young patients suffering not only from venous thromboembolism but also arterial ischemic stroke, in addition to other thrombophilic factors.


Assuntos
Isquemia Encefálica/sangue , Lipoproteína(a)/análise , Adolescente , Isquemia Encefálica/epidemiologia , Estudos de Casos e Controles , Criança , Pré-Escolar , Comorbidade , Encefalite/sangue , Encefalite/epidemiologia , Feminino , Cardiopatias Congênitas/sangue , Cardiopatias Congênitas/epidemiologia , Humanos , Hiperlipidemias/sangue , Hiperlipidemias/epidemiologia , Lactente , Recém-Nascido , Infarto da Artéria Cerebral Média/sangue , Infarto da Artéria Cerebral Média/epidemiologia , Infarto da Artéria Cerebral Posterior/sangue , Infarto da Artéria Cerebral Posterior/epidemiologia , Masculino , Doença de Moyamoya/sangue , Doença de Moyamoya/epidemiologia , Recidiva , Fatores de Risco , Turquia/epidemiologia
18.
J Atheroscler Thromb ; 16(4): 410-8, 2009 Aug.
Artigo em Inglês | MEDLINE | ID: mdl-19672030

RESUMO

AIM: A new antibody reacted with an epitope in Lp(a) that has undergone oxidation treatment, but is not present in native Lp(a), was developed. Thus, we determined serum oxidized Lp(a) concentration in healthy volunteers, and coronary artery disease (CAD), diabetes mellitus (DM), and hypertensive patients. METHODS: We measured serum levels of oxidized Lp(a), Lp(a), LDL-cholesterol and HDL-cholesterol in 122 consecutive patients who underwent routine coronary angiography and had significant coronary artery stenosis (>75%), and 164 age-matched healthy volunteers. Moreover, serum native Lp(a), oxidized Lp(a) concentration, and pulse wave velocity (PWV) were determined in 181 hypertensive patients. RESULTS: Oxidized Lp(a) level in CAD patients with DM was significantly higher than in healthy volunteers (p<0.01). Moreover, serum oxidized Lp(a) concentration showed a significant positive correlation with pulse wave velocity, an index of arteriosclerosis (r=0.431, p<0.01). Of importance, the deposition of oxidized Lp(a) was readily detected in calcified areas of coronary arteries in patients with myocardial infarction. CONCLUSION: The present study demonstrated that oxidized Lp(a) may be a new risk factor for coronary artery disease. As the deposition of oxidized Lp(a) was detected in calcified areas of coronary arteries, oxidized Lp(a) might be implicated in endothelial dysfunction.


Assuntos
Calcinose/sangue , Doença da Artéria Coronariana/sangue , Endotélio Vascular/fisiopatologia , Lipoproteína(a)/sangue , Anticorpos Monoclonais , Estudos de Casos e Controles , Doença da Artéria Coronariana/patologia , Estenose Coronária/sangue , Diabetes Mellitus/sangue , Feminino , Humanos , Hipertensão/sangue , Lipoproteína(a)/análise , Lipoproteína(a)/imunologia , Masculino , Pessoa de Meia-Idade , Oxirredução , Fatores de Risco
19.
J Am Coll Cardiol ; 53(23): 2186-96, 2009 Jun 09.
Artigo em Inglês | MEDLINE | ID: mdl-19497447

RESUMO

OBJECTIVES: This study sought to define the relationship between oxidative biomarkers, cardiovascular disease (CVD) risk factors, and inflammatory and thrombosis biomarkers. BACKGROUND: Elevated levels of oxidized phospholipids (OxPL) on apolipoprotein B particles (apoB) represent a novel biomarker of CVD. Previous studies suggest that an increase in OxPL/apoB reflects a positive response to statins and a low-fat diet. METHODS: This study measured OxPL/apoB, lipoprotein (a) [Lp(a)], and oxidized low-density lipoprotein (OxLDL) biomarkers, consisting of immunoglobulin (Ig)G and IgM autoantibodies to malondialdehyde (MDA)-low-density lipoprotein (LDL) and IgG and IgM apoB-100 immune complexes (IC/apoB), at baseline and after 16 weeks of treatment with atorvastatin 80 mg/day or placebo in 2,342 patients with acute coronary syndromes (ACS) enrolled in the MIRACL (Myocardial Ischemia Reduction With Aggressive Cholesterol Lowering) trial. RESULTS: At baseline, potentially atheroprotective IgM autoantibodies and IgM IC/apoB were lower in male patients, diabetic patients, and patients >65 years of age. Patients with an LDL level greater than the median (122 mg/dl) had higher levels of OxPL/apoB, Lp(a), and OxLDL biomarkers compared with those who had an LDL level less than the median. Atorvastatin resulted in significantly larger changes in all biomarkers in female patients, patients age <65 years, patients with LDL cholesterol <122 mg/dl, nonsmokers, and nondiabetic patients (p < 0.0001 for all). In particular, a significant increase in OxPL/apoB in response to atorvastatin was noted in all 20 subgroups evaluated. Weak or no significant correlations were noted between all OxLDL biomarkers and C-reactive protein, serum amyloid A, tissue plasminogen activator, interleukin-6, intercellular adhesion molecule, vascular cell adhesion molecule, P-selectin, and E-selectin at randomization and 16 weeks. CONCLUSIONS: In patients with ACS, baseline levels of oxidative biomarkers varied according to specific CVD risk factors and were largely independent of inflammatory biomarkers. Atorvastatin uniformly increased OxPL/apoB levels in all subgroups studied. Future studies are warranted to assess whether the increase in OxPL/apoB levels reflects the benefit of effective therapeutic interventions and prediction of new CVD events.


Assuntos
Síndrome Coronariana Aguda/tratamento farmacológico , Anticolesterolemiantes/uso terapêutico , LDL-Colesterol , Ácidos Heptanoicos/uso terapêutico , Fosfolipídeos , Pirróis/uso terapêutico , Espécies Reativas de Oxigênio , Síndrome Coronariana Aguda/imunologia , Síndrome Coronariana Aguda/fisiopatologia , Idoso , Idoso de 80 Anos ou mais , Apolipoproteínas B/química , Apolipoproteínas B/imunologia , Apolipoproteínas B/metabolismo , Atorvastatina , Autoanticorpos/análise , Biomarcadores/análise , LDL-Colesterol/análise , LDL-Colesterol/imunologia , LDL-Colesterol/metabolismo , Estudos de Coortes , Feminino , Humanos , Imunoglobulina G/análise , Imunoglobulina M/análise , Inflamação/fisiopatologia , Lipoproteína(a)/análise , Masculino , Pessoa de Meia-Idade , Oxirredução , Fosfolipídeos/análise , Fosfolipídeos/metabolismo , Fatores de Risco , Tromboembolia
20.
Angiología ; 61(3): 119-128, mayo-jun. 2009. tab, graf
Artigo em Espanhol | IBECS | ID: ibc-75112

RESUMO

Introducción. Actualmente, la valoración del aneurisma de aorta abdominal (AAA) infrarrenal asintomáticose realiza únicamente con pruebas de imagen seriadas. Buscamos un marcador plasmático útil como indicador de la actividaddel AAA y potencial valor pronóstico. Pacientes y métodos. Obtuvimos muestras de sangre periférica de 35 pacientescon AAA (13 AAA 30-39 mm; 11 40-49 mm; 11 >= 50 mm) y 35 controles. Determinamos la concentración plasmáticade proteína C reactiva (PCR), alfa1-antitripsina y lipoproteína(a). Registramos: datos clínicos, diámetro aórtico(ecografía/TC) en el momento de la extracción y crecimiento del AAA en el año previo. Analizamos la correlación entrecada proteína y el diámetro y crecimiento aórticos con los tests de Mann-Whitney, Kruskal-Wallis, Spearman y regresiónlineal. Resultados. Los pacientes eran mayoritariamente varones (n =33; 94,3%), con edad 71 ± 6,8 (54-83) años. El diámetrodel AAA (n = 35) era 45 ± 12 (30-71) mm, con crecimiento (n = 25) 3,1 ± 3,1 (0-10) mm/año previo. Las tres proteínaspresentaban concentraciones mayores en los pacientes que los controles: PCR 4,1 (1,9-7,3) frente a 1,9 (0,5-4,9)mg/L (p = 0,026); alfa1-antitripsina 147 (131-168) frente a 125,5 (113,8-135,5) mg/dL (p < 0,0001); lipoproteína(a) 47(20-117,5) frente a 27 (9-47) mg/dL (p = 0,022). Encontramos correlaciones positivas PCR-diámetro AAA (r = 0,46; p =0,007) y alfa1-antitripsina-crecimiento AAA (r = 0,55; p = 0,004), sin correlación entre lipoproteína(a)-diámetro/crecimientoAAA (p > 0,52). Las concentraciones de PCR estaban influidas por la toma de estatinas (p = 0,036). No existíancorrelaciones en los controles para ninguno de los marcadores (p > 0,22). Conclusiones. La alfa1-antitripsina pareceprometedora como marcador biológico de la actividad del AAA. La PCR muestra correlación con el tamaño del AAA, perose ve influida por las estatinas. Se descarta la utilidad de la lipoproteína(a)(AU)


Introduction. Current assessment of asymptomatic infrarenal abdominal aortic aneurysms (AAA) is donesolely with serial image techniques. We try to find a useful serological biomarker of AAA activity with potentialprognostic value. Patients and methods.We obtained peripheral blood samples from 35 AAA patients (13 3-3.9 cm AAA;11 4-4.9 cm AAA; 11 >= 5 cm AAA) and 35 controls. We quantified the serum concentration of C-reactive protein(CRP), alpha1-antitrypsin and lipoprotein(a). We registered: clinical data, aortic diameter (ultrasound/CT) at the timeof blood sample harvest, and AAA growth in the previous 12 months. We analysed the correlation between each proteinand the aortic diameter and growth, using Mann-Whitney, Kruskal-Wallis and Spearman’s tests and linear regression.Results. The AAA patients were mostly male (n = 33; 94.3%) and aged 71 ± 6.8 (54-83) years. The AAA diameter (n =35) was 45 ± 12 (30-71) mm, with expansion (n = 25) 3,1 ± 3,1 (0-10) mm/previous year. The levels of the three proteinswere significantly higher in the AAA patients compared to the controls: CRP 4.1 (1.9-7.3) v. 1.9 (0.5-5) mg/L (p = 0.026);alpha1-antitrypsin 147 (131-168) v. 125.5 (114-135.5) mg/dL (p < 0.0001); lipoprotein(a) 47 (20-117.5) v. 27 (9-47)mg/dL (p = 0.022). We found positive correlations CRP-AAA diameter (r = 0.46; p = 0.007) and alpha1-antitrypsin-AAAgrowth (r = 0,55; p = 0,004), but no association between lipoprotein(a) and AAA diameter or expansion (p > 0.52). CRPconcentrations were influenced by statin intake (p = 0.036). There were no correlations for any of the proteins in thecontrol group (p > 0.22). Conclusions. Alpha1-antitrypsin seems promising as a biomarker of AAA activity. CRP showscorrelation with AAA size, but is influenced by statin intake. Lipoprotein(a) has not proved useful(AU)


Assuntos
Humanos , Masculino , Feminino , Pessoa de Meia-Idade , Idoso , Idoso de 80 Anos ou mais , Aneurisma da Aorta Abdominal/diagnóstico , Aneurisma da Aorta Abdominal/etiologia , Aneurisma da Aorta Abdominal/imunologia , Aneurisma da Aorta Abdominal/fisiopatologia , Proteína C-Reativa/análise , Proteína C-Reativa/imunologia , alfa 1-Antitripsina/análise , Lipoproteína(a)/análise , Biomarcadores
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA